Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06225310 · ClinicalTrials.gov registry record · Phase 1
A Trial of Selinexor, Ruxolitinib and Methylprednisolone
A Phase 1 study of Multiple Myeloma in Relapse and Multiple Myeloma, Refractory, sponsored by Oncotherapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06225310: Recruiting Phase 1 study of Multiple Myeloma in Relapse and Multiple Myeloma, Refractory, sponsored by Oncotherapeutics.
NCT06225310 is a Phase 1 study of Multiple Myeloma in Relapse and Multiple Myeloma, Refractory that is actively recruiting participants, run by Oncotherapeutics. The registered enrollment target is 30 participants, below the 49-participant average among 12 other Multiple Myeloma in Relapse trials with a reported enrollment target (39% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06225310, a Phase 1 study of Multiple Myeloma in Relapse and Multiple Myeloma, Refractory, is actively recruiting participants, sponsored by Oncotherapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Selinexor, a first-in-class, oral selective exportin 1 (XPO1) inhibitor, has shown promise in pre-clinical and clinical studies. It functions by inhibiting the nuclear export protein XPO1, resulting in the accumulation of tumor suppressor proteins and inhibition of oncoprotein mRNAs, which is selectively lethal to myeloma cells. Selinexor has demonstrated activity in combination with various drugs, including glucocorticoids and proteasome inhibitors, leading to its FDA approval for the treatment of relapsed or refractory multiple myeloma.
Primary Outcome
● A standard 3 + 3 dose escalation schedule will be used for all escalations
Conditions Studied
Interventions
- DRUG Selinexor
- DRUG Ruxolitinib
- DRUG Methylprednisolone
Study Locations (1)
California
- Berenson Cancer Center - West Hollywood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-08-06 |
| Est. Completion | 2027-05-01 |
| Phase | Phase 1 |
What NCT06225310 shows while recruiting
NCT06225310 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 49-participant average among 12 other Multiple Myeloma in Relapse trials with a reported enrollment target (39% lower).
The record links to 2 conditions, with Multiple Myeloma in Relapse appearing as the primary indexed condition, and to 3 interventions - of which Selinexor is the first listed.
NCT06225310 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06225310 about?
NCT06225310 is a clinical study titled "A Trial of Selinexor, Ruxolitinib and Methylprednisolone". Selinexor, a first-in-class, oral selective exportin 1 (XPO1) inhibitor, has shown promise in pre-clinical and clinical studies. It functions by inhibiting the nuclear export protein XPO1, resulting in the accumulation of tumor suppressor proteins and inhibition of oncoprotein mRNAs, which is select...
What is the current status of trial NCT06225310?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2024-08-06. Estimated completion is 2027-05-01.
What conditions does trial NCT06225310 study?
This clinical trial studies the following conditions: Multiple Myeloma in Relapse, Multiple Myeloma, Refractory.
What interventions are being tested in trial NCT06225310?
The interventions under investigation include: Selinexor (DRUG), Ruxolitinib (DRUG), Methylprednisolone (DRUG).
Who is sponsoring clinical trial NCT06225310?
This trial is sponsored by Oncotherapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06225310 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma in Relapse
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06225310's enrollment target sits among peer trials
30 6th of 12 higher than 6 of 12 other Multiple Myeloma in Relapse trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma in Relapse trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
LMY-920 for Treatment of Relapsed or Refractory Myeloma
RECRUITING · Phase 1
-
Ixazomib + Pomalidomide + Dexamethasone In MM
ACTIVE NOT RECRUITING · Phase 1
-
Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)
ACTIVE NOT RECRUITING · Phase 1
-
Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma
COMPLETED · Phase 1
-
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI